Navigation Links
Hot Line IV: Late-breaking trials on heart failure and acute coronary syndrome
Date:9/2/2013

AMSTERDAM, The Netherlands The blood pressure lowering drug aliskiren did not improve coronary artery disease when given to patients who had prehypertension, results of the Aliskiren Quantitative Atherosclerosis Regression Intravascular Ultrasound Study (AQUARIUS) reveal.

The findings, reported at the European Society of Cardiology Congress with simultaneous publication in the Journal of the American Medical Association, offer new insight into the value of lowering blood pressure beyond prehypertensive goals, suggested lead investigator Stephen Nicholls MBBS, PhD, Deputy Director at the South Australian Health and Medical Research Institute, Professor of Cardiology at the University of Adelaide and Consultant Cardiologist at the Royal Adelaide Hospital in Adelaide, Australia.

"In the AQUARIUS study, although greater blood pressure lowering was observed in the aliskiren treatment group, we did not observe significant slowing of disease progression," he noted.

"While these findings do not support the use of aliskiren for regression or prevention of progression of coronary atherosclerosis, prespecified exploratory findings in the trial suggests there may be some other potential benefits in patients with pre-existing coronary artery disease and blood pressure levels treated to goalalthough the current clinical findings are inconclusive," he added.

AQUARIUS was a prospective, randomized, multicenter, double-blind clinical trial conducted at 103 centers in Europe, Australia and North and South America.

It included patients aged 35 years or older with angiographic evidence of coronary artery disease, prehypertensive blood pressure at baseline (systolic blood pressure between 125 and 139 mmHg and diastolic blood pressure less than 90 mmHg) and two additional cardiovascular risk factors. Eligibility required a target blood vessel for imaging with at least 20% and less than 50% stenosis.

After receiving aliskiren 150 mg for 1 week to assess tolerability a total of 613 participants were randomized to receive either aliskiren 300 mg (n=305) or placebo daily (n=308).

Baseline intravascular ultrasonography was used to indentify a target artery for imaging with the primary endpoint of the study being percent atheroma volume (PAV), and a secondary outcome being total atheroma volume (TAV) - measures of the amount of plaque present in the coronary artery.

Among the 458 participants (74.7%) who remained in the study for more than 72 weeks, there were no statistically significant differences in primary or secondary outcomes between those treated with aliskiren or placebo.

"We observed a trend towards a favorable effect on plaque progression in the aliskiren group, although the difference from the placebo group was not statistically significant," said Dr. Nicholls. "As a result, the overall result was considered neutral."

PAV decreased by 0.33% in the aliskiren group and increased by 0.11% in the placebo group (P=0.08), and TAV, decreased by 4.vs 2.1mm3 respectively (P=0.18).

Regression of PAV was observed in 56.9% of aliskiren-treated patients and 48.9% of placebo-treated patients (P=0.09), whereas TAV regressed in 64.4% vs 57.5% respectively (P=0.13).

However, pre-specified exploratory findings showed significantly greater blood pressure reductions in the aliskiren-treated group (systolic -2.9 vs -0.8 mmHg, P=0.007; and diastolic -2.0 vs. -0.4 mmHg, P=0.003).

The exploratory analysis also revealed a favorable effect on clinical events, which was "a surprising result, given that the study was small," said Dr. Nicholls.

There were fewer major cardiovascular events (8.5%vs. 16.2%, P=0.004), and non-fatal myocardial infarctions (0.3% vs.2.6%, P=0.02) in the aliskiren group), however, these findings should be interpreted cautiously he stressed.

"They represent a prespecified exploratory endpoint in a trial not formally powered to assess clinical outcomes and are based on small numbers of events, but should be considered hypothesis-generating findings that may warrant further investigation."

The findings add to the ongoing debate over what is the ideal blood pressure for patients with coronary disease, he said.

"The guidelines say for most patients that is 140 mmHg, although we do not have large trials to tell us definitively whether a patient at 135 mmHg is OK or whether we should do more. There are some suggestions within this study that there may be some extra benefit, but the findings are inconclusive and we need larger studies."


'/>"/>

Contact: ESC Press Office
press@escardio.org
44-773-005-7146
European Society of Cardiology
Source:Eurekalert

Related medicine news :

1. Mesh Lawsuits Move Forward, as Federal Multidistrict Litigation Prepares for First Bellwether Trials in Ethicon Vaginal Mesh Lawsuits, Bernstein Liebhard LLP Reports
2. Making it less of a trial to find important medical evidence: Faculty of 1000 launch F1000Trials
3. New poll shows minority populations support clinical trials to improve health of others
4. Pradaxa Lawsuit Attorneys at Wright & Schulte LLC Report on Scheduling of Bellwether Trials in Federal Pradaxa Bleeding Lawsuits
5. How to boost Hispanics participation in clinical trials? Relate to them, Moffitt study shows
6. Medtronic Infuse Lawsuit News: Bernstein Liebhard LLP Awaits Expected Release of Medtronic-Commissioned Analysis of Infuse Bone Graft Trials
7. Transvaginal Mesh Lawyers at Wright & Schulte LLC Look Ahead to Upcoming Vaginal Mesh Lawsuit Bellwether Trials
8. Late breaking clinical trials introduced for first time at EHRA EUROPACE 2013
9. Experts to present data addressing patient and physician barriers to clinical trials
10. ERT Delivers In-country Support for Japan-Based Clinical Trials
11. Cancer biorepository speeds clinical trials, drug development, Moffitt analysis shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare ... Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during ... , The annual award competition recognizes editorial and design excellence across a range of ...
(Date:10/12/2017)... Wesley Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... Chapel is holding a treadmill relay – Miles by Moonlight to raise money for ... by donating $300 or more. , Teams will work together to keep their ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy ... health literacy software tool, and the Cancer Patient Education Network (CPEN), an independent ... today announce a new strategic alliance. , As CPEN’s strategic partner, HLI ...
(Date:10/12/2017)... Miramar, FL (PRWEB) , ... October 12, 2017 ... ... is presenting the latest in wound care advancements to physician colleagues, skilled nursing ... lecture is titled, "Navigating the Treacherous Waters of Wound Care." , "At many ...
(Date:10/12/2017)... CHICAGO (PRWEB) , ... October ... ... innovator in life sciences content management, presents its enhanced Pepper Flow promotional ... Oct. 16 -18, 2017. Pepper Flow’s increased insight-driven capabilities help marketers streamline ...
Breaking Medicine News(10 mins):
(Date:9/18/2017)... 2017 EpiVax, Inc. ("EpiVax") a ... immune engineering, today announced a new NIH-funded ... ... and presents a challenge for traditional flu ... be effective. Using state-of-the-art bioinformatics and molecular modeling methods, ...
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis , the ... chains, has published the first annual edition of its Global CSR Risk ... 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly ... ... Performance Index ...
(Date:9/12/2017)... Sept. 12, 2017  ValGenesis Inc., the global ... is pleased to announce the appointment of Dr. ... its Board of Directors and Chairman of Advisory ... life science companies to manage their entire validation ... paper in this process. Furthermore, ValGenesis VLMS enables ...
Breaking Medicine Technology: